$JBS

JBS Maintains Overweight Rating -- Price Target Raised to $18.00

JP Morgan maintained an Overweight rating on JBS, raising its price target to $18.00 from $17.50. The company's P/E ratio is 12.04x, above its 5-year median of 6.02x. JBS has a GF Score of 58, indicating moderate performance, with strengths in profitability and growth but weaknesses in valuation. Insiders sold $2.54M in shares over the last three months.

Original reporting
Published Oct 9, 2026, 7:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 10, 2026, 4:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$JBS
Bullish
medium confidence
Mentioned
$JBS
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$JBSBullishMed
01

Why it matters

The rating upgrade suggests analysts see growth potential, but valuation concerns remain.

02

Market read

Primary analyst rating update with modest target increase; limited trading relevance.

03

What to watch

Insider selling of $2.5 M in the past three months may temper enthusiasm.

Relevance 6/10Novelty 6/10Timing: today

Background

JBS is a global protein food company with a market cap of ~$13.8 B, operating in the consumer packaged goods space.

Company-level read

Ticker impact

$JBSBullishMedium confidence
Context

JP Morgan maintained an Overweight rating on JBS and raised the price target to $18.00.

Expected impact

likely upward pressure as investors price in the higher target.

Evidence & confidence

The rating change is a primary disclosure and signals confidence, but the target increase is modest.

Market effects

May reinforce positive sentiment for the consumer defensive sector.

Limited to markets where JBS trades; no broad regional effect.

Low global impact beyond JBS investors.

Counterpoint

The modest target raise could be seen as insufficient given the stock's overvaluation.

Key entities

  • JP Morgan

    Maintained Overweight rating and raised price target.

Related articles

$JBSMed

Brazil Meat Stock Falls 4% on Bird Disease

Brazil's MBRF shares fell 4% after Newcastle disease was found on a turkey farm, raising concerns about potential export pauses to China. The outbreak was confirmed in Santa Catarina, and the farm is under quarantine. China, which took 10% of Brazil's chicken exports, may restrict imports, impacting MBRF's revenue. JBS, another meat group, also saw a decline in shares.